Dapagliflozin Alters Plasma Metabolome in Patients With Type 1 Diabetes During Ketosis
- 1Division of Endocrinology, Metabolism, & Lipid Research Washington University School of Medicine St. Louis Missouri USA
- 2Departments of Chemistry, Medicine, and the Center for Mass Spectrometry & Metabolic Tracing Washington University School of Medicine St. Louis Missouri USA
- 3Division of Endocrinology & Metabolism University of Virginia Charlottesville Virginia USA
Abstract
Aims: Use of sodium‐glucose cotransporter 2 inhibitors (SGLT2i) in patients with type 1 diabetes (T1D) is limited by increased risk of ketoacidosis. We aimed to determine metabolic pathways affected by SGLT2i treatment in adults with T1D during ketosis induced by insulin withdrawal.
Materials and Methods: Plasma metabolomic and lipidomic analysis by ultra‐high‐performance liquid chromatography/mass spectrometry was performed at baseline and after supervised insulin withdrawal in 17 adults with T1D treated with usual care (UC) and (DP) dapagliflozin (10 mg daily for 14 days).
Results: Plasma glucose levels were lower, and ketone levels were higher after insulin withdrawal in DP compared to UC. Pathway analysis of differentially altered metabolites revealed that DP altered amino acids and TCA cycle metabolites during ketosis. DP treatment increased citrate and aconitate at baseline, with a trend towards increased branched chain ketoacids and acylcarnitines. Citrate, aconitate, α‐ketoglutarate and malate were increased during insulin withdrawal after UC whereas insulin withdrawal after DP resulted in unchanged α‐ketoglutarate and malate and significantly decreased fumarate and succinate. Acetylcarnitine was significantly higher during insulin withdrawal after DP compared to UC. DP effected subtle changes in amino acids and amino acid derivatives. Symmetric dimethylarginine and pseudouridine were significantly elevated at baseline and after insulin withdrawal after DP. Lipidomics revealed increased very long TG species in DP and differences in phospholipids, particularly phosphatidylcholine.
Conclusion: In adults with T1D, dapagliflozin alters TCA cycle metabolites, amino acid metabolites and certain lipids during insulin withdrawal. Future work will validate findings and further investigate the metabolic basis of SGLT2i‐mediated ketoacidosis risk.
Related
- Short-term clinical efficacy and recorded adverse events of semaglutide combined with dapagliflozin in patients with type 2 diabetes mellitus and chronic kidney disease
- Changes in CBC-derived inflammatory indices following dapagliflozin initiation in patients with type 2 diabetes mellitus
- Case Report: Diabetic ketosis-associated hemichorea-hemiballism in an elderly patient with longstanding poorly controlled type 2 diabetes mellitus
- Diminished arginine bioavailability during hyperglycaemia distinguishes individuals with A−β+ ketosis-prone diabetes from those with type 2 diabetes: implications for the pathogenesis of ketoacidosis in A−β+ ketosis-prone diabetes
- Dapagliflozin vs. Acetazolamide in Patients With Acute Heart Failure: A Randomized Controlled Trial (CHOICE‐AHF)
BibTeX
@article{yang2026dapagliflozin,
title = {{Dapagliflozin Alters Plasma Metabolome in Patients With Type 1 Diabetes During Ketosis}},
author = {Rosa Yang and Kevin Cho and Max C. Petersen and Kai E. Jones and Gary J. Patti and Janet B. McGill and Samantha A. DiGruccio},
journal = {Diabetes, Obesity \& Metabolism},
year = {2026},
month = sep,
doi = {10.1111/dom.71390},
url = {https://doi.org/10.1111/dom.71390},
note = {CC BY-NC 4.0},
}
RIS
TY - JOUR
TI - Dapagliflozin Alters Plasma Metabolome in Patients With Type 1 Diabetes During Ketosis
AU - Rosa Yang
AU - Kevin Cho
AU - Max C. Petersen
AU - Kai E. Jones
AU - Gary J. Patti
AU - Janet B. McGill
AU - Samantha A. DiGruccio
PY - 2026
DA - 2026/09/28
JO - Diabetes, Obesity & Metabolism
DO - 10.1111/dom.71390
UR - https://doi.org/10.1111/dom.71390
AB - Aims: Use of sodium‐glucose cotransporter 2 inhibitors (SGLT2i) in patients with type 1 diabetes (T1D) is limited by increased risk of ketoacidosis. We aimed to determine metabolic pathways affected by SGLT2i treatment in adults with T1D during ketosis induced by insulin withdrawal. Materials and Methods: Plasma metabolomic and lipidomic analysis by ultra‐high‐performance liquid chromatography/mass spectrometry was performed at baseline and after supervised insulin withdrawal in 17 adults with T1D treated with usual care (UC) and (DP) dapagliflozin (10 mg daily for 14 days). Results: Plasma glucose levels were lower, and ketone levels were higher after insulin withdrawal in DP compared to UC. Pathway analysis of differentially altered metabolites revealed that DP altered amino acids and TCA cycle metabolites during ketosis. DP treatment increased citrate and aconitate at baseline, with a trend towards increased branched chain ketoacids and acylcarnitines. Citrate, aconitate, α‐ketoglutarate and malate were increased during insulin withdrawal after UC whereas insulin withdrawal after DP resulted in unchanged α‐ketoglutarate and malate and significantly decreased fumarate and succinate. Acetylcarnitine was significantly higher during insulin withdrawal after DP compared to UC. DP effected subtle changes in amino acids and amino acid derivatives. Symmetric dimethylarginine and pseudouridine were significantly elevated at baseline and after insulin withdrawal after DP. Lipidomics revealed increased very long TG species in DP and differences in phospholipids, particularly phosphatidylcholine. Conclusion: In adults with T1D, dapagliflozin alters TCA cycle metabolites, amino acid metabolites and certain lipids during insulin withdrawal. Future work will validate findings and further investigate the metabolic basis of SGLT2i‐mediated ketoacidosis risk.
SN - 1462-8902
SN - 1463-1326
ER -